Supplementary Table S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Authors:
- Johann de BonoJBJohann de Bono
- Ramesh K. RamanathanRRRamesh K. Ramanathan
- Lida MinaLMLida Mina
- Rashmi ChughRCRashmi Chugh
- John GlaspyJGJohn Glaspy
- Saeed RafiiSRSaeed Rafii
- Stan KayeSKStan Kaye
- Jasgit SachdevJSJasgit Sachdev
- John HeymachJHJohn Heymach
- David C. SmithDSDavid C. Smith
- Joshua W. HenshawJHJoshua W. Henshaw
- Ashleigh HerriottAHAshleigh Herriott
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)